Anti Phospholipase A2 Receptor Antibody Positivity C5558376
Presence of antibodies targeting kidney filters, commonly linked to membranous nephropathy. Often requires monitoring and may need immunosuppressive treatment.
Key facts at a glance
- ICD-10
- N28.9
- ICD-11
- GA00.0
- Body system
- renal
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Changes in urination or swelling
(renal)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Proteinuria
(renal)Peripheral edema
(renal)Gross hematuria
(renal)Hypoalbuminemia
(renal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Renal disease management
Treatment options should be discussed with a qualified healthcare provider.
Renal function surveillance
Regular monitoring of kidney function, proteinuria, and anti-PLA2R antibody levels to detect membranous nephropathy development early.
Immunosuppressive therapy
If membranous nephropathy with nephrotic syndrome develops, immunosuppressive agents such as rituximab or cyclophosphamide may be indicated.
Additional treatment options
Kidney-friendly diet
Sodium restriction and moderate protein intake help manage blood pressure and reduce kidney workload in patients with nephropathy.
dietarySupportive care with ACE inhibitors/ARBs
RAAS blockers provide renoprotection by reducing proteinuria and slowing kidney disease progression.
medicationKidney biopsy
Definitive diagnosis of membranous nephropathy may require kidney biopsy when clinical presentation warrants histological confirmation.
procedureWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti Phospholipase A2 Receptor Antibody Positivity C5558376?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.
Beck LH Jr, Salant DJ. Membranous nephropathy and the phospholipase A2 receptor: 2020 perspective. Annu Rev Pathol. 2020;15:345-362.
Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase-A2-receptor autoantibodies and its clinical utility in patients with membranous nephropathy. J Nephrol. 2014;27(6):663-669.
Chen X, Liu G, Wang Q, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2019;14(7):1032-1042.
Medication Comparisons
Compare medications used to treat Anti Phospholipase A2 Receptor Antibody Positivity C5558376. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy